Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(15 sites)
United States
City of Hope, Duarte, California Yale, New Haven, Connecticut Memorial Healthcare System, Hollywood, Florida Northside Hospital, Atlanta, Georgia John Hopkins University, Baltimore, Maryland Mass General Hospital, Boston, Massachusetts Karmanos Cancer Institute, Detroit, Michigan Hackensack University Medical Center, Hackensack, New Jersey Columbia University, New York, New York Mount Sinai, New York, New York University North Carolina, Chapel Hill, North Carolina UPenn, Philadelphia, Pennsylvania Baylor University Medical Center, Dallas, Texas MD Anderson, Houston, Texas Froedert and Medical College of Wisconsin, Milwaukee, Wisconsin